Intellia Therapeutics Inc Stock
The price for the Intellia Therapeutics Inc stock decreased slightly today. Compared to yesterday there is a change of -€0.030 (-0.260%).
Currently there is a rather positive sentiment for Intellia Therapeutics Inc with 23 Buy predictions and 7 Sell predictions.
With a target price of 25 € there is potential for a 117.39% increase which would mean more than doubling the current price of 11.5 € for Intellia Therapeutics Inc.
Our community identified positive and negative aspects for Intellia Therapeutics Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Intellia Therapeutics Inc stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Intellia Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | -0.260% | 11.833% | -6.753% | 4.675% | 47.707% | -67.793% | -77.912% |
| Chromadex Corp | -0.930% | -4.545% | -17.647% | -19.231% | -23.636% | 159.339% | -45.455% |
| Cardio3 Biosciences S.A. | -3.780% | -18.681% | 182.443% | -30.320% | 174.074% | -67.714% | -94.032% |
| Polynovo Ltd | 1.870% | -2.727% | -13.008% | -48.558% | -21.324% | -61.511% | -65.033% |
Comments
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for NTLA provided by MarketBeat
News
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares
On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
Intellia Therapeutics (NASDAQ: NTLA) and Iovance Biotherapeutics (NASDAQ: IOVA) are relatively innovative biotech companies. However, due to company-specific headwinds, both have seen their shares